Chandrababu Naidu Govt Allots Land to This Multibagger Stock; Company Plans Rs 5,630 Crore Investment and 6,350 Jobs

In the past month, Indian equity benchmark indices have turned volatile, with the BSE Sensex declining by 3.70 per cent during the same period. However, one stock has bucked the trend and delivered handsome returns.

That stock is Laurus Labs. The Laurus Labs share price has surged by 13.7 per cent over the last month. Over the past two years, the stock has turned multibagger, delivering a remarkable return of 137 per cent. On a year-to-date (YTD) basis, the stock has gained approximately 38 per cent, thereby outperforming both the BSE Sensex and the BSE Healthcare Index.

In a recent development, Laurus Labs announced that the Government of Andhra Pradesh, led by Chief Minister N. Chandrababu Naidu, has allotted 531.77 acres (five hundred thirty-one acres and seventy-seven cents) of land in IP Rambilli Phase-II of Anakapalli District to the company. This land will be used for the establishment of Laurus Pharma Zone (LPZ), where the company plans to set up manufacturing units for pharmaceutical products.

The Government of Andhra Pradesh has issued G.O.Ms.No.136, dated July 27, 2025, confirming the land allotment.

Laurus Labs has projected an investment of Rs 5,630 crore and aims to generate employment for 6,350 people in three phases over a period of eight years. With this allotment, the company has secured a key component for its future expansion—land for large-scale operations. The employment potential is particularly significant at a time when TCS is reportedly planning to lay off 12,000 IT employees.

In its recently announced Q1FY26 results (for the quarter ended June 30, 2025), Laurus Labs reported a 31 per cent year-on-year (YoY) growth in revenue, while net profit surged 1,154 per cent YoY to Rs 163 crore.

The company has made healthy progress in starting the financial year, with increased contributions from its CDMO business and continued advancement of its pipeline with Big Pharma clients. Laurus Labs is now focused on commercial execution, realizing the full potential of its mid- and late-stage pipeline programs, and rapidly enhancing service capabilities to meet the complex needs of its customers.

In the management conference call, the company highlighted strong momentum in its CDMO business, driven by sustained demand for its high-value, integrated offerings. It achieved robust growth in Q1FY26, primarily due to several mid- to late-stage NCE (New Chemical Entity) deliveries and increased sales from new manufacturing assets.

Disclaimer: The article is for informational purposes only and not investment advice.